Skip to Content
Merck
All Photos(1)

Documents

S6826

Sigma-Aldrich

Stiripentol

≥98% (HPLC)

Synonym(s):

4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol, Diacomit

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H18O3
CAS Number:
49763-96-4
Molecular Weight:
234.29
EC Number:
256-480-9
MDL number:
MFCD00869310
UNSPSC Code:
12352200
PubChem Substance ID:
329824570
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: ≥20 mg/mL

storage temp.

−20°C

SMILES string

CC(C)(C)C(O)\C=C\c1ccc2OCOc2c1

InChI

1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+

InChI key

IBLNKMRFIPWSOY-FNORWQNLSA-N

Application

Stiripentol has been used in pharmacokinetic analysis and as a reference standard in fluorescence spectra analysis.
Stiripentol may be used in GABAA receptor-mediated cell signaling studies.

Biochem/physiol Actions

Anti-convulsant drug

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yushi Inoue et al.
Epilepsia, 50(11), 2362-2368 (2009-06-26)
To survey the treatment situation of Dravet syndrome in Japan and to compare this result with effectiveness of stiripentol (STP) add-on therapy in an open-label multicenter study. Medical records of patients with Dravet syndrome who visited the study institutions during
Elaine C Wirrell et al.
Epilepsia, 54(9), 1595-1604 (2013-07-16)
To review the efficacy and tolerability of stiripentol in the treatment of U.S. children with Dravet syndrome. U.S. clinicians who had prescribed stiripentol for two or more children with Dravet syndrome between March 2005 and 2012 were contacted to request
Janet L Fisher
European journal of pharmacology, 654(2), 160-165 (2011-01-18)
Many patients with refractory epilepsy are treated with polytherapy, and nearly 15% of epilepsy patients receive two or more anti-convulsant agents. The anti-convulsant stiripentol is used as an add-on treatment for the childhood epilepsy syndrome known as severe myoclonic epilepsy
Stéphane Auvin et al.
Epilepsia, 54(12), 2082-2090 (2013-10-15)
After the first positive experimental data in rodents in the early 1970s demonstrating the anticonvulsant effect of stiripentol (STP), in vitro studies showed that STP acts directly on γ-aminobutyric acid A (GABAA ) receptors. Chloride influx is higher when these
Janet L Fisher
Epilepsia, 52 Suppl 2, 76-78 (2011-04-08)
The anticonvulsant stiripentol (Diacomittm) has been shown to have a positive impact on control of seizures for many patients with Dravet syndrome. As with most antiepileptic drugs, stiripentol has multiple mechanisms of action. Its direct anticonvulsant activity is likely due
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service